Cover Image

Intestinal P‐gp activity is reduced in postmenopausal women under breast cancer therapy

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Joao Paulo B. Ximenez, Jurandyr Moreira de Andrade, Adriana Rocha, Eduardo Barbosa Coelho, Guilherme Suarez‐Kurtz, Vera Lucia Lanchote
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Clinical and Translational Science
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A phase I drug–drug interaction study to assess the effect of futibatinib on P‐gp and BCRP substrates and of P‐gp inhibition on the pharmacokinetics of futibatinib
by: Amanda Long, et al.
Published: (2024)

Targeting lysine methyltransferase 2C deficiency: New frontiers in breast cancer therapy and prognosis
by: Shuangmei Tong, et al.
Published: (2026)

Is there a possibility that P‐glycoprotein reduces reproductive toxicity in males but breast cancer resistance protein does not?
by: Zhiheng Yu, et al.
Published: (2024)

From Genotype to Therapeutic Monitoring: Enhancing Tamoxifen Efficacy in Breast Cancer Treatment
by: Ana Flávia Mendes Batista, et al.
Published: (2025)

Stimulator of interferon genes (STING)‐activating nanomedicines: Translating innate immune modulation into effective therapy for triple‐negative breast cancer
by: Harshita Singhai, et al.
Published: (2026)

Matrix metalloproteinase 2‐responsive dual‐drug‐loaded self‐assembling peptides suppress tumor growth and enhance breast cancer therapy
by: Jihong Ma, et al.
Published: (2024)

Targeting biomolecular condensates to inhibit breast cancer
by: Xiaoxue Zhou, et al.
Published: (2025)

Nanomedicine: a frontier of the breast cancer treatment
by: Swarup Sonar, et al.
Published: (2024)

Physiologically Based Pharmacokinetic Modeling of Valemetostat to Inform Dose Recommendations When Coadministered With CYP3A /P‐gp Modulators
by: Akiko Watanabe, et al.
Published: (2025)

Seize the engine: Emerging cell cycle targets in breast cancer
by: Jesús Fuentes‐Antrás, et al.
Published: (2024)

Towards a quantum therapy in cancer
by: Frankie James Rawson
Published: (2025)

Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data
by: Bianca Kruger, et al.
Published: (2024)

Dynamics of the intratumoural microbiome across malignant transformation and treatment in breast cancer
by: Liuliu Quan, et al.
Published: (2025)

Pharmaceutical company payments to Japanese breast cancer practice guideline authors
by: Anju Murayama, et al.
Published: (2024)

Single‐cell transcriptional atlas of human breast cancers and model systems
by: Julia E. Altman, et al.
Published: (2024)

Targeting neutrophils: Mechanism and advances in cancer therapy
by: Shuaixi Yang, et al.
Published: (2024)

Targeting autophagy: A promising approach for the treatment of breast cancer brain metastases
by: Steffan T. Nawrocki, et al.
Published: (2024)

Ferroptosis in breast cancer: From adipocyte–immune–iron regulation to therapeutic application
by: Juan Sun, et al.
Published: (2026)

Copper in colorectal cancer: From copper‐related mechanisms to clinical cancer therapies
by: Yuhong Wang, et al.
Published: (2024)

A plasma‐derived exosomal microRNA signature by small RNA sequencing for early detection of postmenopausal osteoporosis
by: Pan Gao, et al.
Published: (2024)

Milk exosomes: Harnessing nature's duality for cancer therapy
by: Asmit Das, et al.
Published: (2024)

Engineered cell versus modified exosomes in cancer therapy
by: Rajib Dhar, et al.
Published: (2024)

Unlocking oncoembryonic programs for clinical advances in cancer therapy
by: Tosca Dalessi, et al.
Published: (2025)

Inhibition of autophagy antagonizes breast cancer brain metastogenesis and augments the anticancer activity of lapatinib
by: Steffan T. Nawrocki, et al.
Published: (2024)

CD70: An emerging target for integrated cancer diagnosis and therapy
by: Jiatao Hu, et al.
Published: (2025)

Integrated spatial multi‐omics profiling of Fusobacterium nucleatum in breast cancer unveils its role in tumour microenvironment modulation and cancer progression
by: Feng Zhao, et al.
Published: (2025)

Effects of microRNA on the growth and targeted therapy response on lung cancer
by: Mengchen Zhu, et al.
Published: (2024)

Liquid biopsy—A biomarker‐based revolutionising technique in cancer therapy
by: Subham Sarkar, et al.
Published: (2024)

Targeting c‐Myc enhances immunotherapy efficacy in combination with Ras inhibitor in triple‐negative breast cancer
by: Xiaojie Liang, et al.
Published: (2025)

Baseline CD4+ and expansion of γδ T cells correlate with response to durvalumab in triple‐negative breast cancer patients
by: Chiara Massa, et al.
Published: (2024)

Distinct discrepancy in breast cancer organoids recapitulation among molecular subtypes revealed by single‐cell transcriptomes analysis
by: Ziqi Jia, et al.
Published: (2024)

Toward precision oncology: An integrative multi‐omics approach for prognosis prediction and inferred immunotherapy responsiveness in breast cancer
by: Houda Bendani, et al.
Published: (2026)

NCAPH drives breast cancer progression and identifies a gene signature that predicts luminal a tumour recurrence
by: Marina Mendiburu‐Eliçabe, et al.
Published: (2024)

Predictive circulating biomarkers of the response to anti‐PD‐1 immunotherapy in advanced HER2 negative breast cancer
by: Yuhan Wei, et al.
Published: (2025)

RNA methylation‐related inhibitors: Biological basis and therapeutic potential for cancer therapy
by: Huanxiang Chen, et al.
Published: (2024)

Integrating oncolytic adenoviruses into combination cancer therapy: Mechanisms, advances and clinical outlook
by: Vlad Iova, et al.
Published: (2026)

Current status and future perspectives of multi‐modal bacteria‐based cancer therapies
by: Shuai Fan, et al.
Published: (2025)

Diverse potential of chimeric antigen receptor‐engineered cell therapy: Beyond cancer
by: Lvying Wu, et al.
Published: (2025)

Immune‐based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2– breast cancer
by: Eudald Felip, et al.
Published: (2025)

PCDHGB7 inhibits the progression of triple‐negative breast cancer by suppressing XRCC5/MYC‐mediated ribosome biogenesis
by: Ming Shan, et al.
Published: (2025)